Lawrence Otto Klein
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
CRISPR Therapeutics to Share New Data at AHA and ACR 2026. CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.
Transaction History
| ORKA | ▲ Buy | Option Exercise | 25,000 | $195K | 10/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 16,246 | $1.4M | 10/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 8,554 | $719K | 10/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 200 | $17K | 10/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,452 | $235K | 9/15/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 75,000 | $585K | 9/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 6,604 | $600K | 9/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 63,596 | $5.8M | 9/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 4,800 | $444K | 9/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 1,729 | $120K | 6/15/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 1,729 | $71K | 3/16/2026 | View on chart |
| ORKA | ▲ Buy | Grant | 76,700 | $0 | 1/23/2026 | View on chart |
| JSPR | ▲ Buy | Grant | 24,500 | $0 | 10/12/2022 | View on chart |
| CRSP | ▼ Sell | Tax Withholding | 1,229 | $75K | 3/14/2022 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 3,000 | — | 3/11/2022 | View on chart |
| CRSP | ▼ Sell | Tax Withholding | 1,883 | $118K | 3/11/2022 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 4,584 | — | 3/10/2022 | View on chart |
| CRSP | ▼ Sell | Tax Withholding | 11,185 | $774K | 12/6/2021 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 26,667 | — | 12/3/2021 | View on chart |
| CRSP | ▼ Sell | Tax Withholding | 4,207 | $496K | 9/13/2021 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 10,000 | — | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.